Home » Blog » Saifen Technology pricts that its operating income in 2024 will be 315 million yuan,

Saifen Technology pricts that its operating income in 2024 will be 315 million yuan,

Saifen Technology pricts A  yearonyear increase of 28.28%; its operating costs in 2024 will be 92.9354 million yuan,

a yearonyear increase of 31.63%, and the growth rate is basically in line with the operating income; the

net profit attributable to the parent company’s monaco email list 100000 contact leads owners in 2024 will be 53.2083 million yuan, a

yearonyear increase of 1.38%; the net profit attributable to the parent company’s shareholders after

ducting nonrecurring gains and losses will be 52.9106 million yuan, a yearonyear increase of 14.97%.

According to data from the Forwardlooking Industry Research Institute

The global chromatography mia market size is expect to reach US6.9 billion in 2023 and is expect to

reach US9 billion in 2026, with an average annual compound growth rate of 9.26% during 20232026.

The size of China’s chromatography mia market how to use seo share of voice in your marketing is expect to reach RMB 11.2 billion in 2023 and will reach RMB 20.3 billion in 2026, with an average annual compound growth rate of 21.92% during 20232026.

Market size of chromatography mia and biochromatography mia in China, Image source: Prospectus

The major manufacturers in the global analytical chromatography industry include international

mainstream manufacturers such as ThermoFisher, Tosoh, Agilent, etc., and the major manufacturers

in the industrial purification industry include Cytiva, ThermoFisher, MerckKGaA, etc.

In 2023, Saifen Technology’s market share in the domestic analytical chromatography

Market will be approximately 5.16%, the market share in industrial purification (chromatographic

mia) will be approximately 1.02%, and the market share in biomacromolecule chromatography mia will be approximately 1.20%.

The company has more than 5,000 customers philippines numbers in the field of analytical chromatography worldwide,

and has establish good business cooperation relationships with large international pharmaceutical

groups, biopharmaceutical companies and innovative drug companies including Roche, Pfizer, Eli Lilly,

Gan & Lee Pharmaceuticals, Chia Tai Tianqing, Qilu Pharmaceutical, Regeneron, and Moderna, and maintains longterm and stable cooperation with international industry giants such as Agilent and SigmaAldrich. From January to June 2024, the company’s overseas revenue account for 25.11% Saifen Technology pricts.

Scroll to Top